奥美拉唑联合伊托必利治疗反流性食管炎的疗效分析

目的探讨奥美拉唑联合伊托必利治疗反流性食管炎的临床疗效。方法将96例反流性食管炎患者分为奥美拉唑组和法莫替汀组各48例,奥美拉唑组给予奥美拉唑联合伊托必利治疗,法莫替汀组给予法莫替汀联合伊托必利治疗,观察两组患者临床症状改善情况,并进行疗效评定。结果奥美拉唑组临床疗效及胃镜疗效总有效率为100%和93.8%,明显高于法莫替丁组的83.3%、79.2%(P<0.05);两组患者不良反应均较轻微,且发生率比较无显著差异(P>0.05)。结论奥美拉唑联合伊托必利治疗反流性食管炎疗效优于法莫替丁联合伊托必利治疗,值得临床推广应用。

Objective To investigate the clinical efficacy of OME and Itopride on the treatment of reflux esophagitis. Methods 96 cases of reflux esophagitis are divided into the OME group and the Famotidine group （each with 48 cases）. The OME group is treated with OME and Itopride, while the Famotidine group is treated with Famotidine and Itopride. The improvement Of clinical signs of both groups are observed and their efficacies are assessed. Results The ORR of the clinical efficacy and the gastroscopic efficacy of the OME group were 100% and 93.8%, significantly better than 83.3% and 79.2% of the Famotidine group （P〈0.05）. There were slight adverse effects on both groups, and there was no significant difference in the incidence （P〉0.05）. Conclusion OME and Itopride are better than Famotidine and Itopride in efficacy on the treatment of reflux esophagitis, and worth clinical application.